This Week in Managed Care: July 14, 2017
This week, the top managed care news included insurers staying away from HealthCare.gov, where you live can affect your chance of surviving cancer, and a new deal could help people on Medicare with diabetes.
Insurers stay away from HealthCare.gov, where you live can affect your chance of surviving cancer, and a new deal could help people on Medicare with diabetes.
Welcome to This Week in Managed Care, I’m Kelly Davio.
Insurers Avoiding HealthCare.gov Exchanges
Consumers shopping for coverage on HealthCare.gov will have
Said CMS Administrator Seema Verma, “This is further proof the Affordable Care Act is failing. Insurers continue to flee the exchanges, causing Americans to lose their choice for health insurance or lose coverage all together.”
However, supporters of the ACA say uncertainty over the fate of its subsidies have troubled insurers. They note that Senate Majority Leader Mitch McConnell delayed the Senate recess to seek votes for a bill to replace the ACA. To learn more about a new version introduced this week, visit
Rural Americans Face Higher Cancer Mortality Risks
People who live in rural America are less likely to get cancer. But when they do, they are
The study found:
- Cancer rates fell nationwide from 2006 to 2015, but they fell faster in metropolitan counties.
- Cancer rates were higher in the most rural counties, compared with other areas, from 2011 to 2015.
Said Acting CDC Director Dr. Anne Schuchat, “While geography alone can’t predict your risk of cancer, it can impact prevention, diagnosis, and treatment opportunities—and that’s a significant public health problem in the US. Many cancer cases and deaths are preventable and with targeted public health efforts and interventions, we can close the growing cancer gap between rural and urban Americans.”
Novartis' CAR-T Therapy on Cusp of Being First FDA-Approved Gene Therapy
Novartis’ chimeric antigen receptor T-cell therapy for pediatric leukemia, better known as CAR-T cell therapy, is on the cusp of being the first gene therapy approved by FDA. An FDA advisory panel gave the therapy, called CTL019, a green light on Wednesday after a hearing that focused on Novartis’ plans for post-marketing studies.
The therapy, developed at the University of Pennsylvania’s Children’s Hospital of Philadelphia, has worked wonders for some patients but also presents unprecedented safety challenges. Said Dr. Stephen Shuster of Penn, “We’re saving patients who three or four years ago we were at our wit’s end trying to keep alive.”
For more, visit
Deal Between Dexcom and Ascensia Paves Way for Medicare Diabetes Bundle
Finally, an agreement between Dexcom and Ascensia Diabetes
Dexcom’s G5 will be shipped with Ascensia’s Contour blood glucose monitoring system, which patients will use twice a day to calibrate the Dexcom system.
For all of us at the Managed Markets News Network, I’m Kelly Davio. Thanks for joining us.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025